19:58 , Sep 21, 2017 |  BC Innovations  |  Tools & Techniques

On your marks

With less fanfare than the first two waves, a quiet rise in activity is driving a revival of interest in epigenetics, despite little progress in solving the fundamental challenges that have dogged the field from...
02:10 , Feb 14, 2017 |  BioCentury  |  Emerging Company Profile

Divide or conquer

Argonaut Therapeutics Ltd. is attacking cancer by inhibiting an epigenetic regulatory protein that controls a dual role for the E2F1 pathway. By inhibiting the PRMT5 enzyme, the company’s molecules flip the pathway from growth and...
07:00 , Jul 25, 2016 |  BioCentury  |  Finance

Leverage over genes

The decision to invest $55 million in a series A round for Fulcrum Therapeutics Inc. reflects Third Rock Ventures' belief that research tools including induced pluripotent stem cells, CRISPR-Cas9 gene editing and bioinformatics have matured...
07:00 , Mar 21, 2016 |  BioCentury  |  Emerging Company Profile

Targeting toxicity

Novonco Therapeutics Inc. is developing a pipeline of targeted cancer therapies that were designed at City of Hope and University of California Irvine to be less toxic than either first-generation inhibitors, or parent molecules. ...
02:24 , Jan 28, 2016 |  BC Extra  |  Company News

Merck, CRT in deal for PRMT5 inhibitors

Merck & Co. Inc. (NYSE:MRK) partnered with Cancer Research Technology Ltd. to develop inhibitors of protein arginine methyltransferase 5, which the companies said have potential to treat cancer and non-cancer blood disorders. The inhibitors were...
08:00 , Jan 15, 2015 |  BC Innovations  |  Product R&D

Epizyme's mantle piece

Epigenetic modulation notched another target last month when Epizyme Inc. announced a preclinical compound against PRMT5 - an arginine methyltransferase - that shows activity in mouse models of mantle cell lymphoma. The next step is...
07:00 , Jul 31, 2014 |  BC Innovations  |  Translation in Brief

Translational tidbits

Benjamin Boettner, Associate Editor, and Chris Cain, Michael J. Haas and Kai-Jye Lou, Senior Writers  Quantitative boost for CSHL The Simons Foundation has donated $50 million to Cold Spring Harbor Laboratory to establish the Simons Center for...
07:00 , Apr 28, 2014 |  BC Week In Review  |  Company News

Epizyme, GlaxoSmithKline deal

Epizyme will receive a $4 million milestone payment from GlaxoSmithKline under a 2011 deal in which the companies partnered to discover, develop and commercialize small molecule therapeutics targeting histone methyltransferases for cancer and other diseases....
07:00 , Mar 10, 2014 |  BC Week In Review  |  Company News

Epizyme, GlaxoSmithKline deal

Epizyme will receive a $2 million milestone payment from GlaxoSmithKline under a January 2011 deal in which the companies partnered to discover, develop and commercialize small molecule therapeutics targeting histone methyltransferases for cancer and other...
08:00 , Feb 6, 2014 |  BC Innovations  |  Tools & Techniques

RNA is for activation

Although siRNA-based therapeutics have recently been clinically validated as a strategy to knock down gene expression, a lesser-known function for short double-stranded RNAs is their ability to turn on the expression of target genes. Now,...